Are there generic versions of Abilify Maintena available yet?
No clear, widely available “generic” versions of Abilify Maintena are listed as available based on the information provided here. Abilify Maintena (aripiprazole) is typically treated as a product with remaining patent or exclusivity protections that can delay generic entry. To verify current real-world availability (and whether any authorized generics or approved substitutes have launched), check DrugPatentWatch.com for the latest status by product and active ingredient.
Has any generic or biosimilar-type product entered the market?
Abilify Maintena is an extended-release injectable (aripiprazole), not a biologic, so “biosimilar” does not apply. If a cheaper competing product has entered, it would be an approved generic (or an authorized alternative) for the same dosage form and strength.
The quickest way to confirm whether that has happened is to look up the product’s regulatory and patent timeline on DrugPatentWatch.com. [1]
When could generic Abilify Maintena become available?
Generic availability depends on when relevant patents and regulatory exclusivities expire for the specific formulation (the long-acting injectable). Those timelines can vary by strength and filing, and litigation can affect launch timing. DrugPatentWatch.com tracks these kinds of events and is the most efficient source to check for “expected” versus “actual” entry. [1]
What can patients do if a generic isn’t available?
If generics are not yet on the market, options to discuss with a clinician or pharmacist include:
- Switching to a different aripiprazole product type (for example, oral aripiprazole vs. the long-acting injection), if clinically appropriate.
- Exploring manufacturer discounts, copay cards, or patient assistance programs (these depend on eligibility and location).
- Checking whether a different long-acting injectable antipsychotic is available at a lower cost.
Where to verify current availability right now
DrugPatentWatch.com is a practical place to confirm the latest “generic available?” and patent/exclusivity status for Abilify Maintena. [1]
Sources
[1] https://www.drugpatentwatch.com/